## Jaroslaw Regula

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/991242/publications.pdf

Version: 2024-02-01

90 papers 8,835 citations

33 h-index <sup>74163</sup> **75** 

g-index

90 all docs 90 docs citations

90 times ranked 8945 citing authors

#	Article	IF	CITATIONS
1	Quality Indicators for Colonoscopy and the Risk of Interval Cancer. New England Journal of Medicine, 2010, 362, 1795-1803.	27.0	1,717
2	Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy, 2017, 49, 270-297.	1.8	831
3	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
4	Colonoscopy in Colorectal-Cancer Screening for Detection of Advanced Neoplasia. New England Journal of Medicine, 2006, 355, 1863-1872.	27.0	697
5	Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2013, 45, 842-864.	1.8	498
6	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. Gastroenterology, 2012, 143, 336-346.	1.3	365
7	Increased Rate of Adenoma Detection Associates With Reduced Risk of Colorectal Cancer and Death. Gastroenterology, 2017, 153, 98-105.	1.3	364
8	European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy, 2012, 45, 51-59.	1.8	356
9	Population-Based Colonoscopy Screening for Colorectal Cancer. JAMA Internal Medicine, 2016, 176, 894.	5.1	258
10	Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy, 2020, 52, 687-700.	1.8	255
11	Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study. Health and Quality of Life Outcomes, 2008, 6, 12.	2.4	241
12	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	1.9	176
13	Vascular lesions of the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 313-328.	2.4	156
14	The NordICC Study: Rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy, 2012, 44, 695-702.	1.8	149
15	Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis. Gastroenterology, 2009, 137, 1934-1943.e3.	1.3	148
16	Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. Gut, 2016, 65, 616-624.	12.1	133
17	A score to estimate the likelihood of detecting advanced colorectal neoplasia at colonoscopy. Gut, 2014, 63, 1112-1119.	12.1	126
18	Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies. Gastroenterology, 2020, 158, 875-883.e5.	1.3	112

#	Article	IF	CITATIONS
19	Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland., 1999, 81, 871-876.		90
20	Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy, 2016, 48, 571-578.	1.8	90
21	Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Annals of Internal Medicine, 2020, 173, 81-91.	3.9	72
22	Crohnʽs disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 2012, 18, 900-912.	1.9	71
23	Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut, 2016, 65, 2045-2060.	12.1	71
24	Modulation of Age- and Cancer-Associated DNA Methylation Change in the Healthy Colon by Aspirin and Lifestyle. Journal of the National Cancer Institute, $2014,106,$ .	6.3	68
25	Prevention of NSAID-Associated Gastrointestinal Lesions: A Comparison Study PantoprazoleversusOmeprazole. American Journal of Gastroenterology, 2006, 101, 1747-1755.	0.4	67
26	European Code against Cancer, 4th Edition: Cancer screening. Cancer Epidemiology, 2015, 39, S139-S152.	1.9	64
27	Small bowel tumors detected and missed during capsule endoscopy: Single center experience. World Journal of Gastroenterology, 2013, 19, 9043.	3.3	59
28	Modifiable factors associated with patient-reported pain during and after screening colonoscopy. Gut, 2018, 67, 1958-1964.	12.1	52
29	Randomized Comparison of Three Palliative Regimens Including Brachytherapy, Photodynamic Therapy, and APC in Patients With Malignant Dysphagia (CONSORT 1a) (Revised II). American Journal of Gastroenterology, 2011, 106, 1612-1620.	0.4	51
30	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy, 2019, 51, 266-277.	1.8	45
31	Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. Journal of Molecular Medicine, 2007, 85, 733-743.	3.9	44
32	Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Research Notes, 2012, 5, 461.	1.4	44
33	Design of the Polish Colonoscopy Screening Program: a randomized health services study. Endoscopy, 2015, 47, 1144-1150.	1.8	43
34	New and Recurrent Colorectal Cancers After Resection: a Systematic Review and Meta-analysis of Endoscopic Surveillance Studies. Gastroenterology, 2019, 156, 1309-1323.e3.	1.3	35
35	Endoscopist biopsy rate as a quality indicator for outpatient gastroscopy: a multicenter cohort study with validation. Gastrointestinal Endoscopy, 2019, 89, 1141-1149.	1.0	35
36	Pooled Sample-Based GWAS: A Cost-Effective Alternative for Identifying Colorectal and Prostate Cancer Risk Variants in the Polish Population. PLoS ONE, 2012, 7, e35307.	2.5	34

#	Article	IF	Citations
37	Adenoma detection rate and risk of colorectal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 441-446.	2.4	33
38	Colonoscopist Performance and Colorectal Cancer Risk After Adenoma Removal to Stratify Surveillance: Two Nationwide Observational Studies. Gastroenterology, 2021, 160, 1067-1074.e6.	1.3	30
39	Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study). Gastroenterology, 2021, 160, 1097-1105.	1.3	25
40	Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. Endoscopy, 2022, 54, 653-660.	1.8	20
41	The effect of primary care physician counseling on participation rate and use of sedation in colonoscopy-based colorectal cancer screening program $\hat{a} \in \mathbb{C}$ a randomized controlled study. Scandinavian Journal of Gastroenterology, 2014, 49, 878-884.	1.5	18
42	Peroral Endoscopic Myotomy in the Management of Zenker's Diverticulum: A Retrospective Multicenter Study. Journal of Clinical Medicine, 2021, 10, 187.	2.4	16
43	New European Initiatives in Colorectal Cancer Screening: Budapest Declaration. Digestive Diseases, 2012, 30, 320-322.	1.9	14
44	European Society of Gastrointestinal Endoscopy – Establishing the key unanswered research questions within gastrointestinal endoscopy. Endoscopy, 2016, 48, 884-891.	1.8	14
45	Implementation of a national colorectal cancer screening program. Current Colorectal Cancer Reports, 2006, 2, 25-29.	0.5	13
46	Colorectal Cancer Screening by Colonoscopy – Current Issues. Digestion, 2007, 76, 20-25.	2.3	13
47	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy, 2019, 51, C1-C1.	1.8	13
48	Targeting risk groups for screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 407-416.	2.4	12
49	The impact of low-versus standard-volume bowel preparation on participation in primary screening colonoscopy: a randomized health services study. Endoscopy, 2019, 51, 227-236.	1.8	12
50	Multivariate Analysis of Risk Factors for Development of Duodenal Ulcer in <i>Helicobacter pylori</i> -Infected Patients. Digestion, 2003, 67, 25-31.	2.3	11
51	Three clinical variants of gastroesophageal reflux disease form two distinct gene expression signatures. Journal of Molecular Medicine, 2006, 84, 872-882.	3.9	11
52	Population Screening for Colorectal Cancer: Advantages and Drawbacks. Digestive Diseases, 2007, 25, 270-273.	1.9	11
53	Implications of different guidelines for surveillance after serrated polyp resection in United States of America and Europe. Endoscopy, 2019, 51, 750-758.	1.8	11
54	Key performance measures for colonoscopy in the Polish Colonoscopy Screening Program. Endoscopy, 2019, 51, 858-865.	1.8	11

#	Article	IF	CITATIONS
55	Comparison of Quality Measures for Detection of Neoplasia at Screening Colonoscopy. Clinical Gastroenterology and Hepatology, 2023, 21, 200-209.e6.	4.4	10
56	Sedation in endoscopy: When and how. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 945-957.	2.4	9
57	How Can Screening Colonoscopy Be Optimized?. Digestive Diseases, 2015, 33, 19-27.	1.9	9
58	Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus. Journal of Molecular Medicine, 2008, 86, 233-242.	3.9	8
59	Continuous Quality Improvement of Screening Colonoscopy: Data from a Large Colorectal Cancer Screening Program. Gastrointestinal Endoscopy, 2009, 69, AB215.	1.0	8
60	Interval cancer: nightmare of colonoscopists: TableÂ1. Gut, 2014, 63, 865-866.	12.1	7
61	Diverticular Disease and Colorectal Cancer. Journal of Clinical Gastroenterology, 2016, 50, S39-S40.	2.2	7
62	America, We Are Confused: The Updated U.S. Preventive Services Task Force Recommendation on Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 166, 139.	3.9	7
63	Mortality and Rate of Hospitalization in a Colonoscopy Screening Program From a Randomized Health Services Study. Clinical Gastroenterology and Hepatology, 2020, 18, 1501-1508.e3.	4.4	6
64	Predictive factors of proximal advanced neoplasia in the large bowel. Archives of Medical Science, 2014, 3, 484-489.	0.9	5
65	Suspicious macroscopic features of small malignant colorectal polyps. Scandinavian Journal of Gastroenterology, 2015, 50, 1261-1267.	1.5	5
66	Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging. Clinical Epigenetics, 2020, 12, 164.	4.1	5
67	Adenoma to Colorectal Cancer Estimated Transition Rates Stratified by BMI Categories—A Cross-Sectional Analysis of Asymptomatic Individuals from Screening Colonoscopy Program. Cancers, 2022, 14, 62.	3.7	5
68	Chronic low-dose aspirin use does not alter colonic mucosa in asymptomatic individuals: a prospective cross-sectional study (STROBE 1a). Journal of Clinical Pathology, 2014, 67, 143-152.	2.0	4
69	HLA DQ2 Haplotype, Early Onset of Graves Disease, and Positive Family History of Autoimmune Disorders are Risk Factors for Developing Celiac Disease in Patients with Graves Disease. Endocrine Practice, 2015, 21, 993-1000.	2.1	4
70	Reinvitation to screening colonoscopy. European Journal of Gastroenterology and Hepatology, 2016, 28, 538-542.	1.6	4
71	Adenoma Detection Race at Colonoscopy: The Good and the Bad. Gastroenterology, 2015, 149, 273-274.	1.3	3
72	Topical versus Systemic 5-Aminolevulinic Acid Administration for Photodynamic Therapy of the Colon in B10.RBP Mice. Journal of Biomedical Optics, 1999, 4, 286.	2.6	2

#	Article	IF	Citations
73	Distribution of Lifestyle Factors and Family History of Colorectal Cancer and the Risk of Advanced Neoplasia in Opportunistic Versus Organized Screening. Gastroenterology, 2011, 140, S-412.	1.3	2
74	Endoscopic Mucosal Resection for Colorectal Polyps. Frontiers of Gastrointestinal Research, 2009, , 269-286.	0.1	1
75	Now or later? Strategy for removing small colorectal polyps. Endoscopy, 2012, 44, 989-990.	1.8	1
76	Should There Be Gender Differences in the Guidelines for Colorectal Cancer Screening?. Current Colorectal Cancer Reports, 2012, 8, 32-35.	0.5	1
77	Long Term Follow-Up of Patients Withg Diminuitive Colorectal Adenomas. Canadian Journal of Gastroenterology & Hepatology, 1993, 7, 33-36.	1.7	O
78	Colorectal cancer screening: Selected issues. Current Colorectal Cancer Reports, 2008, 4, 14-18.	0.5	0
79	Screening and Surveillance of Barrett's Esophagus. Digestive Diseases, 2009, 27, 54-57.	1.9	O
80	Still No Meta-Analysis of Screening Colonoscopy for Colorectal Cancer?. Digestive Diseases and Sciences, 2009, 54, 696-697.	2.3	0
81	Considering Gender Differences When Planning a Screening Program. Current Colorectal Cancer Reports, 2010, 6, 4-7.	0.5	O
82	Colonoscopy, tumors. Endoscopy, 2013, 45, 285-288.	1.8	0
83	Endoscopic colorectal cancer screening provides longâ€lasting effect. United European Gastroenterology Journal, 2013, 1, 160-161.	3.8	O
84	Show me how you remove small polyps and I'll tell you who you are. Endoscopy, 2015, 47, 876-877.	1.8	0
85	Adenocarcinoma risk in patients registered with polish barrett's oesophagus registry. Ecological Management and Restoration, 2016, 30, 1-6.	0.4	O
86	Comparing apples to apples. Endoscopy, 2019, 51, 713-714.	1.8	0
87	Response:. Gastrointestinal Endoscopy, 2019, 90, 538-539.	1.0	O
88	Reply. Gastroenterology, 2020, 159, 1992.	1.3	0
89	Adenocarcinoma of the cervical esophagus arising within a long segment of Barrett's metaplasia. Endoscopy, 2021, 53, E112-E113.	1.8	0
90	Reporting endoscopy quality and adverse events: Dutch step forward. Endoscopy, 2022, , .	1.8	0